The identification of predictive biomarkers is a critical step in drug discovery. Biomarkers are indispensable to assess the efficacy of candidate therapeutics, to further validate drug targets and to alert for potential toxicity. Also, biomarker analysis might serve phase I, II and III clinical trials.

Our capabilities span a range of diseases and methods are compliant with GLP and EMA recommendations for fluid analysis in CGP clinical studies.

TransMed Research applies a wide variety of analytic techniques at mRNA and protein level to cell lysates, cell culture media, tissues, biological fluids also in the frame of clinical studies. Immunoassays are GLP-accredited and validations are performed in accordance with OECD and FDA guidelines.

  • ELISA for human, rat, mouse, cat, dog, and other animal species
  • multiparametric assay based on Luminex technology for human, rat, mouse, cat, dog, and other animal species (cytokines, Alzheimer disease biomarkers, cardiovascular biomarkers, inflammation biomarkers, endocrine biomarkers, kidney toxicity biomarkers, and others according to request)
  • PCR for mRNA and genotyping (standard, RT-PCR, multiplex RT-PCR)

Examples:

  • Alzheimer’s disease.  We test a number of analytes in cerebrospinal fluid and plasma, including the standard biomarkers (Ab40/42, tau/Ptau) and neuroinflammation markers (TNFalfa, sCD40L). We constantly update assays availability according to the literature and the specific needs of the projects.
  • Neuroinflammation.  We test a number of analytes in cerebrospinal fluid and plasma, including TNFalfa, sCD40L. We constantly update assays availability according to the literature and the specific needs of the projects.
  • Shock and multi-organ failure.  We test a number of analytes in cerebrospinal fluid and plasma, including human, rat and mouse targets (see PDF). We constantly update assays availability according to the literature and the specific needs of the projects.

 

Read more:
https://www.ncbi.nlm.nih.gov/pubmed/22922591
https://www.ncbi.nlm.nih.gov/pubmed/23968157

pdfDownload more info
or email us at info@transmed-research.com